Tilray Brands (TLRY) Change in Accured Expenses (2017 - 2026)
Tilray Brands (TLRY) posted Change in Accured Expenses of -$10.6 million for Q1 2026, down 105.37% on a QoQ basis from -$5.2 million in Q4 2025, and up 18.98% year-over-year from -$8.9 million in Q1 2025.
Tilray Brands (TLRY) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Tilray Brands' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$10.6 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 18.98% year-over-year to -$10.6 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$5.9 million (up 12.42% YoY) and the FY2025 annual result came in at -$22.9 million, down 10919.81% from the prior year.
- Change in Accured Expenses was -$10.6 million for Q1 2026 at Tilray Brands, down from -$5.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $31.2 million in Q2 2024 and bottomed at -$18.0 million in Q4 2023.
- A 5-year average of -$1.4 million and a median of -$6.3 million in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 119.73% — and 2024, when it tumbled 1352.3%.
- Tilray Brands' Change in Accured Expenses stood at $4.3 million in 2022, then plunged by 515.73% to -$18.0 million in 2023, then climbed by 9.01% to -$16.4 million in 2024, then jumped by 68.32% to -$5.2 million in 2025, then sank by 105.37% to -$10.6 million in 2026.
- Business Quant data shows TLRY's Change in Accured Expenses at -$10.6 million in Q1 2026, -$5.2 million in Q4 2025, and -$5.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | -10.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -10.64 Mn |
| Feb 28, 2026 | -10.64 Mn |
| Nov 30, 2025 | -5.18 Mn |
| Nov 30, 2025 | -5.18 Mn |
| Aug 31, 2025 | -5.13 Mn |
| Aug 31, 2025 | -5.13 Mn |
| May 31, 2025 | 15.02 Mn |
| May 31, 2025 | 15.02 Mn |
| Feb 28, 2025 | -13.13 Mn |
| Feb 28, 2025 | -13.13 Mn |
| Nov 30, 2024 | -16.36 Mn |
| Nov 30, 2024 | -16.36 Mn |
| Aug 31, 2024 | -8.47 Mn |
| Aug 31, 2024 | -8.47 Mn |
| May 31, 2024 | 31.19 Mn |
| May 31, 2024 | 31.19 Mn |
| Feb 29, 2024 | -6.54 Mn |
| Feb 29, 2024 | -6.54 Mn |
| Nov 30, 2023 | -17.98 Mn |
| Nov 30, 2023 | -17.98 Mn |